Geode Capital Management
FENC icon

Geode Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Geode Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Buy
402,566
+30,828
+8% +$252K ﹤0.01% 2985
2026
Q1 		$2.29M Buy
371,738
+74,638
+25% +$576K ﹤0.01% 3074
2025
Q4 		$2.29M Sell
297,100
-3,672
-1% -$30.1K ﹤0.01% 3121
2025
Q3 		$2.82M Sell
300,772
-3,825
-1% -$33.1K ﹤0.01% 3067
2025
Q2 		$2.53M Sell
304,597
-6,735
-2% -$46.1K ﹤0.01% 3063
2025
Q1 		$1.9M Buy
311,332
+8,242
+3% +$52.9K ﹤0.01% 3054
2024
Q4 		$1.92M Buy
303,090
+3,792
+1% +$19.4K ﹤0.01% 3144
2024
Q3 		$1.5M Sell
299,298
-2,280
-0.8% -$13.2K ﹤0.01% 3213
2024
Q2 		$1.84M Buy
301,578
+81,824
+37% +$680K ﹤0.01% 3145
2024
Q1 		$2.44M Buy
219,754
+1,164
+0.5% +$11.7K ﹤0.01% 3041
2023
Q4 		$2.45M Buy
218,590
+12,391
+6% +$103K ﹤0.01% 3026
2023
Q3 		$1.55M Buy
206,199
+9,322
+5% +$75.9K ﹤0.01% 3166
2023
Q2 		$1.74M Buy
196,877
+177,370
+909% +$1.47M ﹤0.01% 3156
2023
Q1 		$162K Hold
19,507
– – ﹤0.01% 4145
2022
Q4 		$187K Hold
19,507
– – ﹤0.01% 4139
2022
Q3 		$158K Hold
19,507
– – ﹤0.01% 4340
2022
Q2 		$110K Hold
19,507
– – ﹤0.01% 4553
2022
Q1 		$109K Sell
19,507
-112
-0.6% -$564 ﹤0.01% 4628
2021
Q4 		$86K Sell
19,619
-290
-1% -$2.16K ﹤0.01% 4767
2021
Q3 		$187K Buy
19,909
+1,983
+11% +$14.9K ﹤0.01% 4477
2021
Q2 		$130K Sell
17,926
-151,430
-89% -$1.01M ﹤0.01% 4488
2021
Q1 		$1.05M Buy
169,356
+1,513
+0.9% +$11.4K ﹤0.01% 3538
2020
Q4 		$1.25M Buy
167,843
+12,056
+8% +$91.8K ﹤0.01% 3294
2020
Q3 		$944K Buy
155,787
+5,587
+4% +$39.4K ﹤0.01% 3236
2020
Q2 		$1.25M Buy
+150,200
New +$1.12M ﹤0.01% 3073
2019
Q2 		– Sell
-46,059
Closed -$223K – 4222
2019
Q1 		$223K Buy
46,059
+6,570
+17% +$43.2K ﹤0.01% 3704
2018
Q4 		$251K Buy
39,489
+5,441
+16% +$38K ﹤0.01% 3608
2018
Q3 		$279K Buy
34,048
+4,799
+16% +$44.5K ﹤0.01% 3648
2018
Q2 		$305K Buy
+29,249
New +$347K ﹤0.01% 3594

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM

Geode Capital Management's FENC Position: Q2 2026 in Review

Geode Capital Management increased its Fennec Pharmaceuticals (FENC) stake by 8.3% in Q2 2026, buying an estimated $252K and bringing the position to 402,566 shares worth $4.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

Geode Capital Management first reported a position in FENC in Q2 2018 and has held it in 29 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Geode Capital Management held 402,566 shares of Fennec Pharmaceuticals worth $4.33M as of Q2 2026.
  • Geode Capital Management bought 30,828 Fennec Pharmaceuticals shares in Q2 2026, an estimated $252K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2985 holding.
  • Geode Capital Management first reported a position in Fennec Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.